Page last updated: 2024-11-06

cefpimizole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cefpimizole: semisynthetic cephalosporin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68597
CHEMBL ID2103902
CHEBI ID135868
SCHEMBL ID49108
MeSH IDM0125127

Synonyms (32)

Synonym
84880-03-5
ac 1370
u 63196e
cpiz
CHEBI:135868
cefpimizole
2-[1-[[(6r,7r)-2-carboxy-7-[[(2r)-2-[(5-carboxy-1h-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridin-1-ium-4-yl]ethanesulfonate
cefpimizolum [latin]
cefpimizole [usan:inn]
cefpimizol
cefpimizol [spanish]
24s58uhu7n ,
u 63,196
1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)pyridinium hydroxide, inner salt
pyridinium, 1-((2-carboxy-7-(((((5-carboxy-1h-imidazol-4-yl)carbonyl)amino)phenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)-, hydroxide, inner salt, (6r-(6alpha,7beta(r*)))-
u-63,196
u 63196
cefpimizolum
unii-24s58uhu7n
CHEMBL2103902
u-63196
cefpimizole [mi]
cefpimizole [usan]
pyridinium, 1-((2-carboxy-7-(((((5-carboxy-1h-imidazol-4-yl)carbonyl)amino)phenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)-, hydroxide, inner salt, (6r-(6.alpha.,7.beta.(r*)))-
cefpimizole [who-dd]
cefpimizole [inn]
1-[[(6r,7r)-2-carboxy-7-[(r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium hydroxide, inner salt
SCHEMBL49108
1-{[(6r,7r)-2-carboxy-7-{[(2r)-2-{[(5-carboxy-1h-imidazol-4-yl)(hydroxy)methylidene]amino}-1-hydroxy-2-phenylethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-4-(2-sulfonatoethyl)pyridin-1-ium
2-(1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxy-1h-imidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)pyridinium-4-yl)ethanesulfonate
Q5057293
gtpl10779

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Because VCM has the adverse reaction of nephrotoxicity, we are apprehensive about using VCM with other antibiotics, which might increase this problem."( [Nephrotoxicity and drug interaction of vancomycin (2)].
Nakagawa, Y; Toyoguchi, T, 1996
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, the nephrotoxic effects and pharmacokinetics of VCM were examined in rabbits and compared with those in rabbits administered with VCM and other antibiotics."( [Nephrotoxicity and drug interaction of vancomycin (2)].
Nakagawa, Y; Toyoguchi, T, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Cefpimizole was well tolerated locally and systemically by all the subjects at all administered dosage levels."( Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration.
Lakings, DB; Novak, E; Paxton, LM, 1987
)
1.47
" dosing for 6 or 11 days."( Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.
Friis, JM; Lakings, DB; Lunan, CM; Novak, E; Paxton, LM, 1986
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (90.48)18.7374
1990's4 (9.52)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.42 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.55%)5.53%
Reviews2 (4.55%)6.00%
Case Studies1 (2.27%)4.05%
Observational0 (0.00%)0.25%
Other39 (88.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]